Gyrocardiography- A New Non-invasive Cardiac Measurement Method to Measure Exercise Capacity and Cardiorespiratory Fitness

Precordior

Status: Completed

Conditions: Healthy

Treatments: Diagnostic Test: Ergospirometry; Diagnostic Test: Ergometry

Study type: Observational

Funder types: Industry; Other

Identifiers

NCT05936827

Sport Study

Details and patient eligibility

About

The goal of this study is to produce a solution to measure the cardiorespiratory fitness (CRF), which can be used by commercially available smartphones without extra equipment, add-ons and special know-how.

This observational study with follow-up is to test the feasibility of a new non-invasive cardiac measurement method (gyrocardiography, GCG) in detecting hemodynamic parameters to measure exercise capacity and cardiorespiratory fitness in healthy subjects.

The objective is to produce a solution which can be used to measure the exercise capacity and cardiorespiratory fitness (CRF) of the exercisers, keep-fit athletes and professional athletes using hemodynamic parameters such as:

• Heart rate and Heart rate variability
• Cardiac Strength profile
• Systolic and diastolic phase
• Breathing frequency
• VO2max

Participants are either athletes or non-athletic persons. The athletes will perform spiroergometry and non-athletic persons ergometry to measure the CRF expressed as VO2max.

Following parameters will be measured during the (spiro)ergometry:

• Maximum workload (W)
• VO2max (ml/kg/min)
• HRmax
• Blood lactate
• Respiratory exchange ratio RER (VO2/VCO2)

The GCG measurements for acquiring the hemodynamic parameters are performed before and after the (spiro)ergometry using smartphone. During a 1- minute GCG measurement, the smart phone is placed on the chest in the middle of the sternum.

Enrollment: 102 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age: 18-65 years
• No diagnosed cardiovascular diseases (mild hypertension or hypercholesterolemia are still allowed)
• No medication affecting heart rate (i.e. Beta blocker)
• Signed informed consent

Follow-up visit:

• Belong to non-athletic group
• Intention to change physical activity habits
• Willing to participate to the follow-up visit

Exclusion criteria

• Not meeting inclusion criteria
• Declined to participate
• Resting RR before the ergometry > 180/110mmHg

Trial design

102 participants in 2 patient groups

athletic group

Description:

Moderate to high PA levels according to IPAQ.

Treatment:

Diagnostic Test: Ergospirometry

non-athletic group

Description:

Low levels of PA according to IPAQ.

Treatment:

Diagnostic Test: Ergometry